These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22454065)

  • 1. Antisense-mediated exon skipping to reframe transcripts.
    Turczynski S; Titeux M; Pironon N; Hovnanian A
    Methods Mol Biol; 2012; 867():221-38. PubMed ID: 22454065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense-Mediated Splice Modulation to Reframe Transcripts.
    Titeux M; Turczynski S; Pironon N; Hovnanian A
    Methods Mol Biol; 2018; 1828():531-552. PubMed ID: 30171566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Exon Skipping Restores Type VII Collagen Expression and Anchoring Fibril Formation in an In Vivo RDEB Model.
    Turczynski S; Titeux M; Tonasso L; Décha A; Ishida-Yamamoto A; Hovnanian A
    J Invest Dermatol; 2016 Dec; 136(12):2387-2395. PubMed ID: 27498345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients.
    Goto M; Sawamura D; Nishie W; Sakai K; McMillan JR; Akiyama M; Shimizu H
    J Invest Dermatol; 2006 Dec; 126(12):2614-20. PubMed ID: 16778792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.
    Bornert O; Kühl T; Bremer J; van den Akker PC; Pasmooij AM; Nyström A
    Mol Ther; 2016 Aug; 24(7):1302-11. PubMed ID: 27157667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderation of phenotypic severity in dystrophic and junctional forms of epidermolysis bullosa through in-frame skipping of exons containing non-sense or frameshift mutations.
    McGrath JA; Ashton GH; Mellerio JE; Salas-Alanis JC; Swensson O; McMillan JR; Eady RA
    J Invest Dermatol; 1999 Sep; 113(3):314-21. PubMed ID: 10469327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QR-313, an Antisense Oligonucleotide, Shows Therapeutic Efficacy for Treatment of Dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study.
    Bornert O; Hogervorst M; Nauroy P; Bischof J; Swildens J; Athanasiou I; Tufa SF; Keene DR; Kiritsi D; Hainzl S; Murauer EM; Marinkovich MP; Platenburg G; Hausser I; Wally V; Ritsema T; Koller U; Haisma EM; Nyström A
    J Invest Dermatol; 2021 Apr; 141(4):883-893.e6. PubMed ID: 32946877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa.
    Dang N; Murrell DF
    Exp Dermatol; 2008 Jul; 17(7):553-68. PubMed ID: 18558993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
    Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
    Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro Models for the Evaluation of Antisense Oligonucleotides in Skin.
    Bremer J; van den Akker PC
    Methods Mol Biol; 2022; 2434():185-190. PubMed ID: 35213017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exon 87 skipping of the COL7A1 gene in dominant dystrophic epidermolysis bullosa.
    Koga H; Hamada T; Ishii N; Fukuda S; Sakaguchi S; Nakano H; Tamai K; Sawamura D; Hashimoto T
    J Dermatol; 2011 May; 38(5):489-92. PubMed ID: 21352278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of open reading frame resulting from skipping of an exon with an internal deletion in the COL7A1 gene.
    Cserhalmi-Friedman PB; McGrath JA; Mellerio JE; Romero R; Salas-Alanis JC; Paller AS; Dietz HC; Christiano AM
    Lab Invest; 1998 Dec; 78(12):1483-92. PubMed ID: 9881948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A founder synonymous COL7A1 mutation in three Danish families with dominant dystrophic epidermolysis bullosa pruriginosa identifies exonic regulatory sequences required for exon 87 splicing.
    Covaciu C; Grosso F; Pisaneschi E; Zambruno G; Gregersen PA; Sommerlund M; Hertz JM; Castiglia D
    Br J Dermatol; 2011 Sep; 165(3):678-82. PubMed ID: 21574979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
    Popplewell LJ; Malerba A; Dickson G
    Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the position of the premature termination codon in COL7A1 correlate with the clinical severity in recessive dystrophic epidermolysis bullosa?
    Ishiko A; Masunaga T; Ota T; Nishikawa T
    Exp Dermatol; 2004 Apr; 13(4):229-33. PubMed ID: 15086338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recessive dystrophic epidermolysis bullosa caused by COL7A1 hemizygosity and a missense mutation with complex effects on splicing.
    Titeux M; Mejía JE; Mejlumian L; Bourthoumieu S; Mirval S; Tonasso L; Heller M; Prost-Squarcioni C; Hovnanian A
    Hum Mutat; 2006 Mar; 27(3):291-2. PubMed ID: 16470588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Trattner L; Liemberger B; Bischof J; Kocher T; Ablinger M; Nyström A; Obermayer A; Klausegger A; Guttmann-Gruber C; Wally V; Bauer JW; Hofbauer JP; Koller U
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for recessive dystrophic epidermolysis bullosa.
    Titeux M; Pendaries V; Hovnanian A
    Dermatol Clin; 2010 Apr; 28(2):361-6, xii. PubMed ID: 20447504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel type VII collagen gene mutations resulting in severe recessive dystrophic epidermolysis bullosa.
    Massé M; Cserhalmi-Friedman PB; Falanga V; Celebi JT; Martinez-Mir A; Christiano AM
    Clin Exp Dermatol; 2005 May; 30(3):289-93. PubMed ID: 15807692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.